Regeneron Pharmaceuticals Inc (REGN) Unusual Options Activity Today

Checking REGN unusual options activity helps you spot when traders are making outsized bets on Regeneron Pharmaceuticals Inc before the broader market catches on. Regeneron Pharmaceuticals Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor REGN unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching REGN unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking REGN unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and REGN unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.

In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Catalysts rarely arrive without a footprint, and REGN unusual options activity is often where that footprint shows up first. Our scanner tracks Regeneron Pharmaceuticals Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at REGN unusual options volume on the call side or chasing put sweeps, Regeneron Pharmaceuticals Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.